CN114191539A - 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 - Google Patents
一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 Download PDFInfo
- Publication number
- CN114191539A CN114191539A CN202111410482.4A CN202111410482A CN114191539A CN 114191539 A CN114191539 A CN 114191539A CN 202111410482 A CN202111410482 A CN 202111410482A CN 114191539 A CN114191539 A CN 114191539A
- Authority
- CN
- China
- Prior art keywords
- active protein
- exosome
- nucleic acid
- sirna
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 73
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 34
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 34
- 239000002131 composite material Substances 0.000 title claims abstract description 24
- -1 small molecule nucleic acid Chemical class 0.000 title claims abstract description 23
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000001814 protein method Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 230000002195 synergetic effect Effects 0.000 claims abstract description 12
- 238000001890 transfection Methods 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 241000713666 Lentivirus Species 0.000 claims abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 7
- 238000010353 genetic engineering Methods 0.000 claims abstract description 7
- 230000004048 modification Effects 0.000 claims abstract description 6
- 238000012986 modification Methods 0.000 claims abstract description 6
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 17
- 108700012411 TNFSF10 Proteins 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 210000003954 umbilical cord Anatomy 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract description 42
- 238000011282 treatment Methods 0.000 abstract description 16
- 201000011510 cancer Diseases 0.000 abstract description 12
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000006907 apoptotic process Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 11
- 238000011068 loading method Methods 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- 102100025222 CD63 antigen Human genes 0.000 description 3
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LQRNAUZEMLGYOX-LZVIIAQDSA-N CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)CCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1COP(O)(O)=O Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)CCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1COP(O)(O)=O LQRNAUZEMLGYOX-LZVIIAQDSA-N 0.000 description 1
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010025461 Cyclin-Dependent Kinase 9 Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012822 autophagy inhibitor Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229950005863 inclisiran Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Optics & Photonics (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
本发明公开了一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用。所述纳米粒子包括来自细胞并载入了活性蛋白的复合外泌体，以及装载在复合外泌体内的小分子核酸。本发明先经过基因工程修饰构建慢病毒载体，通过慢病毒转染将活性蛋白的目的基因整合到细胞上，得到载入了活性蛋白的复合外泌体，再载入治疗核酸siRNA，实现外泌体共载送siRNA和活性蛋白。本发明表明，靶向凋亡抑制基因的siRNA和活性蛋白具有复合协同作用，能高效特异地杀死耐药性癌细胞，并且与抗肿瘤药物组合使用，能进一步提高治疗效果，可实现药物基于外泌体对耐药性癌症的多靶点联合精准治疗，为癌症治疗提供更多更高效的药物。
Description
技术领域
本发明属于纳米载药与肿瘤学技术领域，更具体地，涉及一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用。
背景技术
肿瘤的耐药性是造成肿瘤难以治愈的主要原因，研究表明，肿瘤的复发与转移与耐药性肿瘤干细胞(cancer stem cells，CSCs)具有密切的联系。而CSCs的耐药性主要包括以下两个方面：获得性耐药性和天然耐药性。获得性耐药是指长期暴露于辐射或致癌因子后，CSCs和相近的子代细胞可通过与正常干细胞积累突变的同样机制(点突变、基因激活、基因扩增)等出现新的耐药性；天然耐药性指处于静止期的CSCs具有DNA自我修复能力和APC转运蛋白而获得的与生俱来的耐药性。而细胞周期蛋白依赖性激酶9(cyclindependent kinase9，CDK9)是一种DNA转录调节因子，与细胞凋亡调控有密切的关系。有研究表明，抑制CDK9可以重新激活在表观遗传上被癌症沉默的基因，同时调节凋亡抑制基因的表达，解除癌细胞的凋亡耐药性，致敏其对治疗药物的应答。因此，CDK9是一种潜在的癌症治疗分子靶位。
外泌体是细胞分泌的粒径在30-150nm的细胞外囊泡，外被磷脂双分子层结构，能够透过体内的天然屏障(如血脑屏障)，具有良好的肿瘤靶向性。此外，外泌体在机体内部还具有良好的生物稳定性和生物相容性、低免疫原性和低毒性。外泌体不仅具有细胞间信息传递的作用，还作为一种天然的生物纳米载体，被开发运用于各类分子(包括siRNA)的细胞间传输。与传统的药物载体相比，外泌体作为一种新型的，天然药物载体，显示诸如生物相容性好、免疫原性低，良好的肿瘤靶向性等优点。
小分子干扰核酸(small interfering RNA，siRNA)是一类通常长度为20-25个核苷酸的双链RNA，它进入体内后通过干扰mRNA影响翻译过程，从而沉默该基因的蛋白合成。目前已经有研究表明小干扰核酸疗法Inclisiran作为首创的降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol，LDL-C)的siRNA疗法在欧洲获批用于治疗成人高胆固醇血症及混合性血脂异常，这将是引领慢性疾病治疗的一个全新的革命。但由于siRNA自身结构的不稳定性，在体内实验中通常需要对其进行化学修饰，这些化学修饰可能会改变siRNA的性质甚至影响其基因沉默的效果，且siRNA是无法自主进入细胞的，因此寻求一种行之有效的递载siRNA的方法就成为必要。
目前，已有研究采用外泌体运载siRNA。如现有技术公开了一种复合siRNA纳米载体，是一种以自体肿瘤细胞来源的外泌体脂质膜包裹载送siRNA和血清白蛋白的复合纳米，应用于抗肿瘤。但是，该技术使用外泌体载送的siRNA和血清白蛋白两种分子只是复合载送，两者并无协同治疗效应。为了更好地应用外泌体作为天然药物载体提高治疗效果，寻找一种有效的装载siRNA并联合其他药物用于癌症协同治疗的新策略，对于开发高效的癌症精准治疗纳米药物有巨大的实际应用价值。
发明内容
本发明的目的在于提供一种新的复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子用于癌症的治疗，能复合协同，高效特异地杀死具有耐药性的癌细胞，为癌症治疗提供了基于外泌体的更高效的药物联合治疗策略。
本发明的第二个目的在于提供所述制备方法及其应用。
本发明的第三个目的在于提供一种抗肿瘤药物组合物。
本发明的上述目的是通过以下技术方案给予实现的：
一种复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子，包括来自细胞并载入了活性蛋白的复合外泌体，以及装载在复合外泌体内的小分子核酸。
本发明对细胞进行基因工程修饰后，得到载入了活性蛋白的复合外泌体，利用该复合外泌体装载小分子核酸纳米粒子可以对癌症进行联合治疗，还可以利用该复合外泌体装载小分子核酸纳米粒子联合其他药物用于癌症的治疗。
优选地，所述细胞包括间充质干细胞、骨髓干细胞、胚胎干细胞、脐带干细胞、肿瘤细胞、肿瘤干细胞、免疫细胞或成纤维细胞中的一种。
优选地，所述活性蛋白为TRAIL蛋白。
优选地，所述小分子核酸为siRNA-CDK9和/或siRNA-eif5B。
特别地，本发明采用的复合外泌体运载的小分子核酸，其siRNA可为癌症沉默基因，也可为其他的siRNA，是能根据需求不同可以变动的，并且不止是针对癌症治疗，在原则上是采用外泌体进行运载，所以是可以采用其他siRNA。
上述复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子的制备方法，包括以下步骤：
S1.基因工程修饰构建慢病毒载体，通过慢病毒转染将活性蛋白的目的基因整合到细胞上，在培养箱中培养，提取外泌体，即得到载入了活性蛋白的复合外泌体；
S2.将步骤S1中得到的载入了活性蛋白的复合外泌体，进行重悬后与小分子核酸混合，冰上超声处理，摇床孵育，得到复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子。
优选地，所述步骤S1中基因工程修饰包括慢病毒转染、逆转录病毒转染或腺病毒转染中的一种。
优选地，所述步骤S2中载入了活性蛋白的复合外泌体与小分子核酸混合的体积比为3～8:1。
更优选地，所述步骤S2中载入了活性蛋白的复合外泌体与小分子核酸混合的体积比为5:1。
优选地，所述步骤S2中超声处理的条件为：超声10～60s，暂停10～60s，功率10～30％，温度20～35℃，循环次数1～10次。
更优选地，超声处理的条件为：超声30s，暂停30s，功率25％，温度25℃，循环次数6次。
优选地，所述步骤S2中摇床孵育的条件为：在30～40℃孵育0.5～2h。
更优选地，摇床孵育的条件为：在37℃孵育1h。
优选地，所述步骤S1中培养箱的培养条件为：25～40℃，5～10％CO2，10～20h。
更优选地，培养箱的培养条件为：37℃，5％CO2，16h。
本发明提供所述复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子在制备抗肿瘤药物中的应用。
本发明还提供一种抗肿瘤药物组合物，含有上述复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子和抗肿瘤药物。
优选地，所述抗肿瘤药物包括化疗药物、免疫治疗药物、重构肿瘤微环境的药物中的至少一种。
本发明经过基因工程修饰了间充质干细胞然后分离提纯的外泌体，在外泌体上能同时载运siRNA和活性蛋白，使siRNA和活性蛋白能协同表达，结果表明靶向凋亡抑制基因的siRNA和活性蛋白(TRAIL蛋白)的复合协同能高效杀死耐药性的癌细胞。
与现有技术相比，本发明具有以下有益效果：
本发明利用复合外泌体装载小分子核酸，能够大大提高小分子核酸在体内的稳定性，同时也能使其借助外泌体的天然肿瘤趋向性向病灶部位聚集。本发明可解决CSCs耐药性和药物靶向性差的问题，该复合外泌体载入小分子核酸并联合其他药物后通过静脉给药进入血液后，能够高效的蓄积于肿瘤组织、深部穿透进入肿瘤病灶深部并且显著抑制肺癌的生长，明显降低CSCs的分化。且靶向凋亡抑制基因的siRNA和活性蛋白具有复合协同作用，能高效特异地杀死耐药性癌细胞，并且与抗肿瘤药物组合使用，能进一步提高治疗效果，可实现药物基于外泌体对耐药性癌症的多靶点联合精准治疗，为癌症治疗提供更高效的药创新物。
附图说明
图1为EV-T透射电子显微镜照片；
图2为流式细胞仪分析细胞的TRAIL阳性转染率；
图3为TRAIL ELISA试剂盒测出EV和EV-T携带TRAIL的量；
图4为MSCs及EVs中TRAIL表达分析；
图5为HPLC检测siRNA含量结果；
图6为EV-T超声装载siRNA-eif5B后作用Huh7细胞不同时间下的蛋白表达情况；
图7为不同作用条件下A549细胞的存活率；
图8为小鼠皮下肿瘤模型。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明，但实施例并不对本发明做任何形式的限定。除非特别说明，本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明，以下实施例所用试剂和材料均为市购。
实施例1TRAIL基因工程化MSC干细胞及其外泌体的制备与表征
传代培养P2-P4脐带来源间充质干细胞(UC-MSC)(此细胞为某干细胞公司惠赠，也可从新鲜脐带分离培养而来)，将状态良好的干细胞MSC以1×106个/孔的密度接种于细胞培养六孔板，在37℃，5％CO2条件下，细胞培养箱过夜。
对上述培养的MSC细胞进行基因工程化修饰，使用携带TRAIL表达框的慢病毒，以MOI＝3的病毒浓度，采用8μg/mL聚凝胺(polybrene)增强转染，孵育10h；将培养基换成含有10％FBS(胎牛血清)DMEM/F12的新鲜培养基，继续培养2-3天；待细胞长满培养基后，再将细胞转移到培养瓶进行增殖传代培养，得到表达TRAIL的干细胞(MSCflT)。
将六孔板转染后的表达TRAIL的干细胞(MSCflT)消化，离心后取沉淀，再加入250μl裂解液(99％ripa，1％蛋白酶抑制剂)，冰上裂解1h，离心(4℃，10min，12000g)后取上清液，加入5×loading buffer进行加热蛋白(100℃，10min)，再采用BCA试剂盒测试其蛋白浓度后定量。
将上述转染后的MSCflT细胞传代培养后收集其上清液，先低速离心(4℃，10min，1000g)去除死细胞和细胞碎片；然后以0.22μm滤膜过滤除去大于220nm的沉淀外泌体EV-T或其它细胞残片和颗粒等物质；接着可以用100kD超滤离心(4℃，10min，3000g)将外泌体沉淀EV-T溶液浓缩5倍；最后进行超速离心(4℃，2h，120000g)，采用经0.22μm滤膜过滤过的PBS溶液重悬外泌体沉淀EV-T，分装并冻存于-80℃保存备用。
EV-T的透射电子显微镜图如图1所示，经过流式细胞仪分析细胞的TRAIL阳性转染率，结果如图2所示。采用TRAIL ELISA试剂盒测出EV和EV-T携带TRAIL的量结果如图3所示。
取上述转染后的MSC细胞裂解后的上清液及EV-T通过蛋白免疫印迹法检查细胞是否转染成功以及其外泌体的标志蛋白CD63以及其携带的TRAIL情况。结果如图4所示，为MSCs及EVs中TRAIL表达情况，其中图4A表示MSC细胞和表达TRAIL的干细胞(MSCflT)通过蛋白免疫印迹法检测细胞是否转染成功，由图可知MSCflT已经成功转染；图4B表示外泌体的标志蛋白CD63以及其携带的TRAILB情况，由图可知CD63已经成功携带EV-T。
实施例2外泌体装载小分子核酸siRNA-CDK9/siRNA-eif5B
使用的siRNA-CDK9/siRNA-eif5B由广州艾基生物科技有限公司设计合成，其序列为：
Hs-siRNA-CDK9-1 Sense:5’-GUGAUGAAGUUUCCAAAUAdTdT-3’；
Hs-siRNA-CDK9-1 Antisense:5’-UAUUUGGAAACUUUCAUCACdTdT-3’；
Hs-siRNA-CDK9-2 Sense:5’-GGCAGGCUGGAGAGAGAAAdTdT-3’；
Hs-siRNA-CDK9-2 Antisense:5’-UUUCUCUCUCCAGCCUGCCdTdT-3’；
Hseif5B-2012-s：CGGCGACUUGAACAUAGUAAA(dT)(dT)；
Hseif5B-2012-a：UUUACUAUGUUCAAGUCGCCG(dT)(dT)；
Hseif5B-3047-s：GAUGAAUUGAUCCAUGAGUUA(dT)(dT)；
Hseif5B-3047-a：UAACUCAUGGAUCAAUUCAUC(dT)(dT)。
将沉淀外泌体EV-T与siRNA按照质量比5:1进行混合，使用超声仪对其进行超声装载，设置参数为：超声30s，暂停30s，功率25％，温度25℃，循环次数6次。在超声结束后放置在37℃的摇床，孵育1h，帮助外泌体恢复膜结构；装载siRNA后的EV-T利用外泌体沉淀试剂盒沉淀(贝贝生物科技有限公司，郑州)，去掉上清中游离的siRNA，再用PBS溶解后加入ripa裂解液，使包裹siRNA的EV-T将siRNA全部释放出来，再利用HPLC检测siRNA含量结果如图5所示，计算对应的装载率。通过计算装载率得出超声的装载率约为18％。
实施例3Western blotting检测基因沉默后的eif5B蛋白表达情况
将A549和Huh7细胞(购于上海富衡生物科技有限公司)按1×106个/孔的密度种植于细胞培养六孔板，在37℃，5％CO2条件下进行培养箱培养，待融合率达到70％，加入装载了siRNA的EV-T，继续培养72h后，将六孔板转染后的MSC细胞消化，离心取沉淀，加入250μl裂解液(99％ripa，1％蛋白酶抑制剂)，冰上裂解1h，离心(4℃，10min，12000g)后取上清液，加入5×loading buffer加热蛋白(100℃，10min)，再采用BCA试剂盒测试其蛋白浓度后定量，通过蛋白免疫印迹法检测基因沉默情况，结果如图6所示，为eif5B不同时间段的基因沉默情况。
实施例4CCK8检测细胞毒性及对肿瘤细胞的杀伤情况
为了验证装载了siRNA的EV-T对正常细胞的毒性以及对肿瘤细胞的杀伤效果，我们选取了正常细胞MSC和NF，肿瘤细胞A549、Huh7和HepG2，使其在单独的EV-T(包含活性蛋白)、游离的siRNA和复合外泌体载送siRNA作用下，分别检验其细胞活性。
结果由图7可知，在单独的EV-T和游离的siRNA作用下，对正常的细胞和肿瘤细胞的活性基本没有影响；而复合外泌体载送siRNA对正常细胞基本无毒性，对肿瘤细胞有着较好的杀伤效果。
我们还进一步研究发现，在复合外泌体载送siRNA的使用上同时加入氯喹(chloroquine，CQ)一种自噬抑制剂，能进一步的提高复合外泌体载送siRNA对肿瘤细胞的杀伤效果。可能的机理在于氯喹抑制了细胞内溶酶体对进入细胞的外泌体的融合分解，从而促进了外泌体载送siRNA进入细胞核发挥抑制靶分子mRNA作用。
实施例5复合外泌体载送siRNA-CDK9后在A549肿瘤模型中的杀伤情况
从珠海百试通生物科技有限公司购入4-5周龄的BALB/c雌性裸鼠，在SPF级饲养环境下饲养其体重达到20g左右；选取状态良好的小鼠用于皮下肿瘤模型造膜。按照500万/只的细胞数量接种肿瘤细胞造膜，再分别注射Ctrl(空白对照水)，沉淀外泌体EV-T(包含活性蛋白)，siRNA-CDK9，复合外泌体载送siRNA-CDK9(siCDK9@EV-T)，通过皮下注射接种到小鼠皮下，接种28天以后随机将小鼠分为5组：Ctrl，EV-T，siRNA-CDK9，siCDK9@EV-T，按照100ugsiRNA/只，8ng EV-T/只的药物剂量通过皮下注射的方式给药，每次给药间隔2天，共给药7次，最后检测小鼠体内肿瘤细胞的抑制情况。
由结果可知，在治疗完成后发现单独使用的EV-T和siRNA-CDK9基本对高抗性A549肿瘤没有抑制作用，而在使用了复合外泌体载送siRNA-CDK9是可以提高对肿瘤的抑制作用，图8为小鼠皮下肿瘤模型图。
综上所述，先经过基因工程修饰间充质干细胞，使其分泌表达了治疗蛋白的外泌体，分离纯化此外泌体后，再载入治疗核酸siRNA，实现基于外泌体的共载递送siRNA和抗癌蛋白；而与单独的沉淀外泌体EV-T(包含活性蛋白)和siRNA-CDK9相比，采用复合外泌体载送siRNA-CDK9能提高对肿瘤的抑制作用还能高效杀死癌症细胞，这是在单独作用EV-T(包含活性蛋白)和siRNA-CDK9所达不到的效果，表明两种治疗分子的协同效应可显著增强对癌细胞的致死效果；结果表明靶向凋亡抑制基因的siRNA和抗癌蛋白的复合协同能高效特异性地杀死耐药性癌细胞，可实现基于外泌体的对耐药性癌症的多靶点联合精准治疗。
以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，对于本领域的普通技术人员来说，在上述说明及思路的基础上还可以做出其它不同形式的变化或变动，这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明权利要求的保护范围之内。
Claims (10)
1.一种复合载送小分子核酸和协同活性蛋白的外泌体纳米粒子，其特征在于，包括来自细胞并载入了活性蛋白的复合外泌体，以及装载在复合外泌体内的小分子核酸。
2.根据权利要求1所述的纳米粒子，其特征在于，所述细胞包括间充质干细胞、骨髓干细胞、胚胎干细胞、脐带干细胞、肿瘤细胞、肿瘤干细胞、免疫细胞或成纤维细胞中的一种。
3.根据权利要求1所述的纳米粒子，其特征在于，所述活性蛋白为TRAIL蛋白。
4.根据权利要求1所述的纳米粒子，其特征在于，所述小分子核酸为siRNA-CDK9和/或siRNA-eif5B。
5.权利要求1所述纳米粒子的制备方法，其特征在于，包括以下步骤：
S1.基因工程修饰构建慢病毒载体，通过慢病毒转染将活性蛋白的目的基因整合到细胞上，在培养箱中培养，提取外泌体，即得到载入了活性蛋白的复合外泌体；
S2.将步骤S1中得到的载入了活性蛋白的复合外泌体，进行重悬后与小分子核酸混合，冰上超声处理，摇床孵育，得到复合载送小分子核酸和活性蛋白的外泌体纳米粒子。
6.根据权利要求5所述制备方法，其特征在于，所述步骤S1中基因工程修饰包括慢病毒转染、逆转录病毒转染或腺病毒转染中的一种。
7.根据权利要求5或6所述制备方法，其特征在于，所述步骤S2中载入了活性蛋白的复合外泌体与小分子核酸混合的体积比为3～8:1。
8.权利要求1-4任一所述复合载送小分子核酸和协同活性蛋白的纳米粒子在制备抗肿瘤药物中的应用。
9.一种抗肿瘤药物组合物，其特征在于，含有上述权利要求1-4任一所述复合载送小分子核酸和协同活性蛋白的纳米粒子和抗肿瘤药物。
10.根据权利要求9所述组合物，其特征在于，所述抗肿瘤药物包括化疗药物、免疫治疗药物、重构肿瘤微环境的药物中的至少一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410482.4A CN114191539B (zh) | 2021-11-19 | 2021-11-19 | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410482.4A CN114191539B (zh) | 2021-11-19 | 2021-11-19 | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114191539A true CN114191539A (zh) | 2022-03-18 |
| CN114191539B CN114191539B (zh) | 2023-12-01 |
Family
ID=80648847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111410482.4A Active CN114191539B (zh) | 2021-11-19 | 2021-11-19 | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114191539B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116807976A (zh) * | 2023-08-22 | 2023-09-29 | 昆明时光肌生物技术有限公司 | 一种包载药物脂质体及其制备方法和提高外泌体分泌量的方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011358A (zh) * | 2006-12-29 | 2007-08-08 | 浙江大学 | 一种具有高效抗肿瘤活性的纳米结构脂质载体 |
| CN103656674A (zh) * | 2012-08-29 | 2014-03-26 | 上海吉凯基因化学技术有限公司 | 人eIF5B基因的用途及其相关药物 |
| CN109125291A (zh) * | 2018-08-28 | 2019-01-04 | 南通大学 | 复合siRNA纳米载体及其制备方法和应用 |
| WO2019027298A2 (ko) * | 2017-08-04 | 2019-02-07 | 주식회사 에스엘바이젠 | Trail 및 cd를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 암의 예방또는 치료용 약학 조성물 |
| CN111840513A (zh) * | 2020-06-12 | 2020-10-30 | 广东工业大学 | 一种负载促肿瘤凋亡蛋白和抗癌小分子的复合外泌体及其制备方法和应用 |
-
2021
- 2021-11-19 CN CN202111410482.4A patent/CN114191539B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011358A (zh) * | 2006-12-29 | 2007-08-08 | 浙江大学 | 一种具有高效抗肿瘤活性的纳米结构脂质载体 |
| CN103656674A (zh) * | 2012-08-29 | 2014-03-26 | 上海吉凯基因化学技术有限公司 | 人eIF5B基因的用途及其相关药物 |
| WO2019027298A2 (ko) * | 2017-08-04 | 2019-02-07 | 주식회사 에스엘바이젠 | Trail 및 cd를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 암의 예방또는 치료용 약학 조성물 |
| CN109125291A (zh) * | 2018-08-28 | 2019-01-04 | 南通大学 | 复合siRNA纳米载体及其制备方法和应用 |
| CN111840513A (zh) * | 2020-06-12 | 2020-10-30 | 广东工业大学 | 一种负载促肿瘤凋亡蛋白和抗癌小分子的复合外泌体及其制备方法和应用 |
Non-Patent Citations (5)
| Title |
|---|
| J LEMKE ET AL.: "\"Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1\"", CELL DEATH AND DIFFERENTIATION, vol. 21, pages 491 - 502, XP055346725, DOI: 10.1038/cdd.2013.179 * |
| JOSEPH A. ROSS ET AL.: ""Eukaryotic initiation factor 5B (eIF5B) provides a critical cell survival switch to glioblastoma cells via regulation of apoptosis"", CELL DEATH AND DISEASE, vol. 10, no. 57 * |
| ZHENGQIANG YUAN ER AL.: ""TRAIL delivery by MSC derived extracellular vesicles is an effective anticancer therapy"", JOURNAL OF EXTRACELLULAR VESICLES, vol. 6, no. 1, XP055515425, DOI: 10.1080/20013078.2017.1265291 * |
| ZHOU XUNIAN ET AL.: "\"Biology and therapeutic potential of mesenchymal stem cell-derived exosomes\"", CANCER SCIENCE, no. 111, pages 3100 - 3110 * |
| 杜月等: ""间充质干细胞外泌体作为药物递送载体的研究进展"", 中国药学杂志, no. 01, pages 6 - 12 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116807976A (zh) * | 2023-08-22 | 2023-09-29 | 昆明时光肌生物技术有限公司 | 一种包载药物脂质体及其制备方法和提高外泌体分泌量的方法 |
| CN116807976B (zh) * | 2023-08-22 | 2023-11-17 | 昆明时光肌生物技术有限公司 | 一种包载药物脂质体及其制备方法和提高外泌体分泌量的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114191539B (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy | |
| Li et al. | A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody | |
| Zhou et al. | Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment | |
| Dong et al. | Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy | |
| US20210212948A1 (en) | Nanovesicles derived from cell membrane, and use thereof | |
| Qiu et al. | Immunomodulatory‐Photodynamic Nanostimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy | |
| CN111265549A (zh) | 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用 | |
| CN112826808B (zh) | 一种环二核苷酸或其类似物的中性/阳离子混合脂材纳米制剂及其应用 | |
| US20190307794A1 (en) | Method for inducing transdifferentiation of immune cells based on exosomes | |
| Tang et al. | A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration | |
| Cao et al. | Extracellular vesicles as drug vectors for precise cancer treatment | |
| CN112870181A (zh) | 一种复合载药的细胞外囊泡吸入制剂及其制备方法和用途 | |
| Wen et al. | A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy | |
| Cui et al. | Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy | |
| Li et al. | A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes | |
| Gou et al. | Non‐Pore Dependent and MMP‐9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer | |
| Zhang et al. | Precise RNA Editing: Cascade Self‐Uncloaking Dual‐Prodrug Nanoassemblies Based on CRISPR/Cas13a for Pleiotropic Immunotherapy of PD‐L1‐Resistant Colorectal Cancer | |
| Bai et al. | Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles | |
| CN114191539B (zh) | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 | |
| Liu et al. | In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma | |
| Ye et al. | Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment | |
| Shen et al. | Systemic administration with bacteria-inspired nanosystems for targeted oncolytic therapy and antitumor immunomodulation | |
| Liang et al. | Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through RIPK3-triggered necroptotic immunogenic cell death | |
| Ma et al. | Engineered Cell Membrane‐Coated Nanoparticles: New Strategies in Glioma Targeted Therapy and Immune Modulation | |
| Dilsiz | Exosomes as new generation vehicles for drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |